晚期糖基化终末产物在糖尿病血管并发症中的作用
The Role of Advanced Glycation End Products in Diabetic Vascular Complications.
作者信息
Rhee Sang Youl, Kim Young Seol
机构信息
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
出版信息
Diabetes Metab J. 2018 Jun;42(3):188-195. doi: 10.4093/dmj.2017.0105. Epub 2018 May 31.
Abstract
In cases of chronic hyperglycemia, advanced glycation end-products (AGEs) are actively produced and accumulated in the circulating blood and various tissues. AGEs also accelerate the expression of receptors for AGEs, and they play an important role in the development of diabetic vascular complications through various mechanisms. Active interventions for glucose and related risk factors may help improve the clinical course of patients by reducing AGEs. This review summarizes recent updates on AGEs that have a significant impact on diabetic vascular complications.
摘要
在慢性高血糖情况下，晚期糖基化终末产物（AGEs）在循环血液和各种组织中被积极产生并积累。AGEs还会加速AGEs受体的表达，并且它们通过各种机制在糖尿病血管并发症的发展中发挥重要作用。对血糖及相关危险因素的积极干预可能有助于通过减少AGEs来改善患者的临床病程。本综述总结了对糖尿病血管并发症有重大影响的AGEs的最新研究进展。
相似文献
1
The Role of Advanced Glycation End Products in Diabetic Vascular Complications.
Diabetes Metab J. 2018 Jun;42(3):188-195. doi: 10.4093/dmj.2017.0105. Epub 2018 May 31.
2
The Role of Advanced Glycation End Products in Diabetic Vascular Complications.
Diabetes Metab J. 2018 May 31.
3
A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
Curr Vasc Pharmacol. 2017;15(4):352-364. doi: 10.2174/1570161115666170327162639.
4
A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation.
Metabolism. 2017 Jun;71:64-69. doi: 10.1016/j.metabol.2017.03.004. Epub 2017 Mar 9.
5
Advanced glycation end-products and the progress of diabetic vascular complications.
Physiol Res. 2004;53(2):131-42.
6
Advanced glycation end products and diabetic foot disease.
Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S19-24. doi: 10.1002/dmrr.861.
7
[Advanced glycation end products and hyperglycaemia].
Tidsskr Nor Laegeforen. 2006 Jan 12;126(2):155-8.
8
Hyperglycemia and glycation in diabetic complications.
Antioxid Redox Signal. 2009 Dec;11(12):3071-109. doi: 10.1089/ars.2009.2484.
9
Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
J Diabetes. 2017 Feb;9(2):141-148. doi: 10.1111/1753-0407.12475. Epub 2016 Sep 25.
10
Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients.
Gene. 2013 Sep 10;526(2):325-30. doi: 10.1016/j.gene.2013.05.013. Epub 2013 May 27.
引用本文的文献
1
Prognostic value of lipid accumulation product in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction: a retrospective cohort study.
BMC Res Notes. 2025 Jul 31;18(1):335. doi: 10.1186/s13104-025-07405-x.
2
The RAGE Inhibitor TTP488 (Azeliragon) Improves Diabetic Bladder Dysfunction in Leptin-Deficient Obese Mice.
Antioxidants (Basel). 2025 Jun 27;14(7):793. doi: 10.3390/antiox14070793.
3
Considerations on the Development of Therapeutics in Vascular Calcification.
J Cardiovasc Dev Dis. 2025 May 29;12(6):206. doi: 10.3390/jcdd12060206.
4
Affinity on Demand: A One-Pot Method for Synthesis and Sample Enrichment Using TentaGel-Functionalized Resins.
ACS Omega. 2025 Apr 22;10(17):18135-18144. doi: 10.1021/acsomega.5c02738. eCollection 2025 May 6.
5
Exploring the shared genetic landscape of diabetes and cardiovascular disease: findings and future implications.
Diabetologia. 2025 Jun;68(6):1087-1100. doi: 10.1007/s00125-025-06403-9. Epub 2025 Mar 15.
6
Advances in the Regulation of Inflammatory Mediators in Nitric Oxide Synthase: Implications for Disease Modulation and Therapeutic Approaches.
Int J Mol Sci. 2025 Jan 30;26(3):1204. doi: 10.3390/ijms26031204.
7
Intradermal Advanced Glycation End-products Relate to Reduced Sciatic Nerve Structural Integrity in Type 2 Diabetes.
Clin Neuroradiol. 2025 Jan 29. doi: 10.1007/s00062-024-01493-1.
8
Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes.
J Diabetes Sci Technol. 2025 Jan 8:19322968241310850. doi: 10.1177/19322968241310850.
9
Ribose-induced advanced glycation end products reduce the lifespan in Drosophila melanogaster by changing the redox state and down-regulating the Sirtuin genes.
Biogerontology. 2024 Dec 19;26(1):28. doi: 10.1007/s10522-024-10172-0.
10
Effect of Extraction Methods on Chemical Characteristics and Bioactivity of cv. Fubaiju Extracts.
Foods. 2024 Sep 26;13(19):3057. doi: 10.3390/foods13193057.
本文引用的文献
1
Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.
Diabetes Care. 2018 Mar;41(3):570-576. doi: 10.2337/dc17-1740. Epub 2017 Dec 5.
2
Cooking Methods for Red Meats and Risk of Type 2 Diabetes: A Prospective Study of U.S. Women.
Diabetes Care. 2017 Aug;40(8):1041-1049. doi: 10.2337/dc17-0204. Epub 2017 Jun 13.
3
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Mol Med. 2015 Oct 27;21 Suppl 1(Suppl 1):S32-40. doi: 10.2119/molmed.2015.00067.
4
Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.
Lab Invest. 2015 May;95(5):525-33. doi: 10.1038/labinvest.2015.35. Epub 2015 Mar 2.
5
Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
Horm Metab Res. 2014 Sep;46(10):717-21. doi: 10.1055/s-0034-1371892. Epub 2014 Apr 7.
6
Advanced glycation end products and diabetic complications.
Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13.
7
Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.
BMC Cardiovasc Disord. 2013 Mar 5;13:13. doi: 10.1186/1471-2261-13-13.
8
Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus.
J Clin Biochem Nutr. 2013 Jan;52(1):22-6. doi: 10.3164/jcbn.12-40. Epub 2012 Dec 6.
9
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Am J Pathol. 2013 Jan;182(1):132-41. doi: 10.1016/j.ajpath.2012.09.016. Epub 2012 Nov 14.
10
Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase.
Vascul Pharmacol. 2013 Jan;58(1-2):21-30. doi: 10.1016/j.vph.2012.10.003. Epub 2012 Oct 17.
Zotero 插件